• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Sarepta Therapeutics, Inc. - Common Stock (NQ:SRPT)

    22.26 -0.54 (-2.37%)
    Streaming Delayed Price Updated: 10:53 AM EDT, Apr 7, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 373,429
    Open 22.65
    Bid (Size) 22.22 (100)
    Ask (Size) 22.27 (200)
    Prev. Close 22.80
    Today's Range 22.02 - 22.66
    52wk Range 10.41 - 64.80
    Shares Outstanding 93,148,652
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    Ultragenyx Vaults Toward Commercialization as FDA Accepts Landmark Gene Therapy BLA
    In a pivotal moment for the rare disease community and the biotechnology sector, Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) has reached a critical regulatory milestone. The U.S. Food and Drug... 
    Via MarketMinute
    Topics Intellectual Property Lawsuit
    News headline image
    Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Sarepta Therapeutics, Inc.
    Via Business Wire

    Performance

    YTD
    +4.5%
    +4.5%
    1 Month
    +26.2%
    +26.2%
    3 Month
    +5.6%
    +5.6%
    6 Month
    -4.3%
    -4.3%
    1 Year
    -57.5%
    -57.5%

    More News

    Read More
    News headline image
    Biotech Defies Gravity: Sarepta and Corcept Lead Midday Healthcare Rally Amidst Market Volatility
    Via MarketMinute
    Topics Economy Intellectual Property Stocks
    Sarepta Therapeutics (NASDAQ:SRPT) Posts Q4 Revenue Beat Amid Deep Losses and Major Charges ↗
    Via Chartmill
    News headline image
    Sarepta's RNA Renaissance: 35% Surge as siRNA Breakthrough Silences Skeptics
    Via MarketMinute
    News headline image
    Sarepta Therapeutics (SRPT) Stock Surges 34.98% on Breakthrough Clinical Data
    Via MarketMinute
    News headline image
    The RNA Renaissance: Decoding Sarepta Therapeutics’ 34% Surge and the Future of Precision Medicine
    Via Finterra
    Topics Retirement
    Let's have a look at the top gainers and losers one hour before the close of the markets of today's session. ↗
    Via Chartmill
    Wednesday's session: top gainers and losers ↗
    Via Chartmill
    Which stocks are gapping on Wednesday? ↗
    Via Chartmill
    News headline image
    Sarepta Therapeutics (SRPT) at a Crossroads: A 2026 Deep Dive into the Future of Genetic Medicine
    Via Finterra
    Topics Economy Intellectual Property Retirement
    News headline image
    Sarepta Announces First Clinical Data from siRNA Pipeline Targeting FSHD1 and DM1
    From Sarepta Therapeutics, Inc.
    Via Business Wire
    News headline image
    Sarepta to Share First Clinical Data from siRNA Pipeline Targeting FSHD1 and DM1
    From Sarepta Therapeutics, Inc.
    Via Business Wire
    News headline image
    2 Beaten-Down Stocks That Still Aren't Worth Buying ↗
    Via The Motley Fool
    Topics Cannabis
    News headline image
    Sarepta Provides Regulatory Update on AMONDYS 45® and VYONDYS 53®
    From Sarepta Therapeutics, Inc.
    Via Business Wire
    News headline image
    Sarepta Shares Rise As Company Begins Enrollment In Gene Therapy Safety Enhancement Study ↗
    Via Stocktwits
    Topics Death
    News headline image
    Sarepta Announces that Screening and Enrollment are Underway in ENDEAVOR Cohort 8 to Evaluate Enhanced Immunosuppression Regimen as Part of ELEVIDYS Gene Therapy for Non-Ambulant Individuals with Duchenne
    From Sarepta Therapeutics, Inc.
    Via Business Wire
    News headline image
    Sarepta Therapeutics Announces Call for Applications for the 9th Annual Route 79, The Duchenne Scholarship Program
    From Sarepta Therapeutics, Inc.
    Via Business Wire
    News headline image
    Sarepta Therapeutics to Present New Long-Term and Safety Data Across Gene Therapy and Exon-Skipping Programs at 2026 Muscular Dystrophy Association Clinical & Scientific Congress
    From Sarepta Therapeutics, Inc.
    Via Business Wire
    News headline image
    Nasdaq, S&P 500 Futures Tread Caution On Nvidia’s China Risk: Why NFLX, WBD, AAPL, CRM, AI, LRMR Are On Traders' Radar Today ↗
    Via Stocktwits
    Topics Artificial Intelligence ETFs Stocks
    News headline image
    Sarepta Stock Dips After Hours: DMD Drug Blow And CEO Exit Eclipse Q4 Revenue Beat ↗
    Via Stocktwits
    Topics Earnings
    News headline image
    Sarepta (SRPT) Q4 2025 Earnings Call Transcript ↗
    Via The Motley Fool
    Topics Earnings
    News headline image
    Sarepta Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results and Recent Corporate Developments
    From Sarepta Therapeutics, Inc.
    Via Business Wire
    News headline image
    Sarepta Therapeutics Announces Commercial Launch of ELEVIDYS in Japan
    From Sarepta Therapeutics, Inc.
    Via Business Wire
    News headline image
    Sarepta Therapeutics to Present at the TD Cowen 46th Annual Health Care Conference
    From Sarepta Therapeutics, Inc.
    Via Business Wire

    Frequently Asked Questions

    Is Sarepta Therapeutics, Inc. - Common Stock publicly traded?
    Yes, Sarepta Therapeutics, Inc. - Common Stock is publicly traded.
    What exchange does Sarepta Therapeutics, Inc. - Common Stock trade on?
    Sarepta Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Sarepta Therapeutics, Inc. - Common Stock?
    The ticker symbol for Sarepta Therapeutics, Inc. - Common Stock is SRPT on the Nasdaq Stock Market
    What is the current price of Sarepta Therapeutics, Inc. - Common Stock?
    The current price of Sarepta Therapeutics, Inc. - Common Stock is 22.26
    When was Sarepta Therapeutics, Inc. - Common Stock last traded?
    The last trade of Sarepta Therapeutics, Inc. - Common Stock was at 04/07/26 10:53 AM ET
    What is the market capitalization of Sarepta Therapeutics, Inc. - Common Stock?
    The market capitalization of Sarepta Therapeutics, Inc. - Common Stock is 2.07B
    How many shares of Sarepta Therapeutics, Inc. - Common Stock are outstanding?
    Sarepta Therapeutics, Inc. - Common Stock has 2B shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.